1027 articles
Phase II trial shows petrelintide, a weekly amylin injectable, achieves meaningful weight loss with far fewer nausea and vomiting events than GLP-1 drugs.
Head-to-head biologic trials and novel cell therapies signal major advances for autoimmune and inflammatory disease treatment.
The ACHIEVE-5 trial shows orforglipron added to basal insulin significantly lowered HbA1c and reduced body weight without raising hypoglycemia risk.
Phase III trial shows retatrutide cuts body weight up to 28% in 80 weeks, also slashing pain and sleep apnea severity.
A Cambridge-developed AI-engineered vaccine protected against multiple coronaviruses in 39 volunteers, pointing toward pandemic-proof immunity.
A study of 110,000+ women found GLP-1 users had ~30% lower breast cancer risk, sparking plans for clinical trials.
Stanford researchers found genetic variants in ~10% of people that blunt GLP-1 drug effectiveness, pointing toward precision diabetes care.
New research links resistance training to lower mortality and reveals liquid biopsies may paradoxically delay cancer diagnoses in resource-limited settings.
Pfizer's berobenatide produced up to 12.1% weight loss over 28 weeks, with monthly dosing maintaining momentum — but still lags behind Eli Lilly's Zepbound.
New safety data on retatrutide reveal cardiac signals alongside impressive weight loss results in diabetic patients. Here's what we know.
A review of 8,000 participants confirms collagen boosts skin elasticity and eases osteoarthritis pain, but fails to improve athletic performance.
Aging raises deficiency risks for B12, D, and protein. Learn which supplements are evidence-backed and which are unnecessary or harmful.
